TacticScaleWhat Kenvue Does & How It Makes Money (KVUE)
Updated October 2026 · reflects Kenvue's latest reported financials
Consumer health company behind Tylenol, Neutrogena, Listerine and BAND-AID. Kenvue makes money by selling branded consumer health products, including OTC medicines, skin and beauty products, and essential health items, across North America, Europe, the Middle East, Africa, Asia-Pacific and Latin America.
How Kenvue makes money
Kenvue makes money by selling branded consumer health products, including OTC medicines, skin and beauty products, and essential health items, across North America, Europe, the Middle East, Africa, Asia-Pacific and Latin America.
What Kenvue does
Kenvue Inc. is a consumer health company headquartered in Summit, New Jersey, and incorporated in 2022. It sells products in the United States and other parts of North America, Europe, the Middle East, Africa, Asia-Pacific and Latin America. Its business has three segments. Self Care covers OTC medicines for cough, cold and allergy, pain, digestive health, smoking cessation and eye care, plus digital diagnostics and telemedicine. Skin Health and Beauty covers face, body, hair and sun care. Essential Health covers oral care, baby care, women's health and wound care. The company owns a large set of well-known brands. These include Tylenol, Motrin, Benadryl, Zyrtec, Nicorette and Sudafed in self care; Neutrogena, Aveeno, OGX, Lubriderm and Rogaine in skin and beauty; and Listerine, BAND-AID, Johnson's, Neosporin, Stayfree and o.b. in essential health. This mix of household names across many categories and regions gives it a wide base of everyday consumer demand.
Products & services
- Tylenol
- Zyrtec
- Neutrogena
- Aveeno
- Listerine
- BAND-AID
What is Kenvue worth?
On an owner-earnings DCF, Kenvue's most-likely value is about $18 versus a recent price near $18 (1% below fair value). But TacticScale only calls a stock undervalued when the price sits below its conservative no-growth floor (~$11) with a margin of safety — so the honest verdict here is “Fairly priced — no edge.” Fair value earns its keep only at the extremes, not in the wide middle.
Price sits in the normal range — fair value isn't actionable here; it earns its keep only when price drops below the no-growth floor, or runs to roughly double the optimistic case.
Analysis, not advice. Fair value is a margin-of-safety estimate from a deterministic owner-earnings DCF, not a price target or recommendation. See the full breakdown →
Related companies
Prestige Consumer Healthcare (PBH) · Viatris (VTRS) · Envista (NVST) · Kimberly-Clark (KMB)